Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Singulair launched in U.K. at price of $1.50 per day; U.S. review deadline is Feb. 21.

Executive Summary

MERCK SINGULAIR ADD-ON ASTHMA THERAPY INDICATION IN EUROPE allows use of the once-a-day oral leukotriene receptor antagonist "in the treatment of asthma as add-on therapy in those patients with mild to moderate asthma who are inadequately controlled on inhaled corticosteroids and in whom `as-needed' short acting ~-agonists provide inadequate clinical control of asthma," the European summary of product characteristics reads. Merck launched Singulair (montelukast) in the U.K. Feb. 4. The product's approval is pending at FDA with a user fee review deadline of Feb. 21.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel